PMID- 34646841
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211015
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Therapeutic Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells in 
      Recovering From Murine Pulmonary Emphysema Under Cigarette Smoke Exposure.
PG  - 713824
LID - 10.3389/fmed.2021.713824 [doi]
LID - 713824
AB  - Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) were shown to have 
      potential for immunoregulation and tissue repair. The objective of this study was 
      to investigate the effects of hUC-MSCs on emphysema in chronic obstructive 
      pulmonary disease (COPD). The C57BL/6JNarl mice were exposed to cigarette smoke 
      (CS) for 4 months followed by administration of hUC-MSCs at 3 x 10(6) (low dose), 
      1 x 10(7) (medium dose), and 3 x 10(7) cells/kg body weight (high dose). The 
      hUC-MSCs caused significant decreases in emphysema severity by measuring the mean 
      linear intercept (MLI) and destructive index (DI). A decrease in neutrophils (%) 
      and an increase in lymphocytes (%) in bronchoalveolar lavage fluid (BALF) were 
      observed in emphysematous mice after hUC-MSC treatment. Lung levels of 
      interleukin (IL)-1beta, C-X-C motif chemokine ligand 1 (CXCL1)/keratinocyte 
      chemoattractant (KC), and matrix metalloproteinase (MMP)-12 significantly 
      decreased after hUC-MSC administration. Significant reductions in tumor necrosis 
      factor (TNF)-alpha, IL-1beta, and IL-17A in serum occurred after hUC-MSC administration. 
      Notably, the cell viability of lung fibroblasts improved with hUC-MSCs after 
      being treated with CS extract (CSE). Furthermore, the hUC-MSCs-conditioned medium 
      (hUC-MSCs-CM) restored the contractile force, and increased messenger RNA 
      expressions of elastin and fibronectin by lung fibroblasts. In conclusion, 
      hUC-MSCs reduced inflammatory responses and emphysema severity in CS-induced 
      emphysematous mice.
CI  - Copyright (c) 2021 Chen, Chen, Lin, Chen, Wen, Hsiao, Chou, Chung and Chuang.
FAU - Chen, Xiao-Yue
AU  - Chen XY
AD  - Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical 
      University, Taipei, Taiwan.
AD  - School of Respiratory Therapy, College of Medicine, Taipei Medical University, 
      Taipei, Taiwan.
FAU - Chen, Yi-Ying
AU  - Chen YY
AD  - School of Respiratory Therapy, College of Medicine, Taipei Medical University, 
      Taipei, Taiwan.
FAU - Lin, Willie
AU  - Lin W
AD  - Meridigen Biotech Co., Ltd., Taipei, Taiwan.
FAU - Chen, Chien-Han
AU  - Chen CH
AD  - Meridigen Biotech Co., Ltd., Taipei, Taiwan.
FAU - Wen, Yu-Chieh
AU  - Wen YC
AD  - Meridigen Biotech Co., Ltd., Taipei, Taiwan.
FAU - Hsiao, Ta-Chih
AU  - Hsiao TC
AD  - Graduate Institute of Environmental Engineering, National Taiwan University, 
      Taipei, Taiwan.
FAU - Chou, Hsiu-Chu
AU  - Chou HC
AD  - Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, 
      Taipei Medical University, Taipei, Taiwan.
FAU - Chung, Kian Fan
AU  - Chung KF
AD  - National Heart and Lung Institute, Imperial College London, London, United 
      Kingdom.
FAU - Chuang, Hsiao-Chi
AU  - Chuang HC
AD  - School of Respiratory Therapy, College of Medicine, Taipei Medical University, 
      Taipei, Taiwan.
AD  - Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho 
      Hospital, Taipei Medical University, New Taipei City, Taiwan.
AD  - Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei 
      Medical University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20210927
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8502916
OTO - NOTNLM
OT  - COPD
OT  - cigarette smoke
OT  - emphysema
OT  - inflammation
OT  - stem cell
COIS- WL, C-HC, and Y-CW are employed by Meridigen Biotech Co., Ltd. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2021/10/15 06:00
MHDA- 2021/10/15 06:01
PMCR- 2021/09/27
CRDT- 2021/10/14 06:39
PHST- 2021/05/24 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/10/14 06:39 [entrez]
PHST- 2021/10/15 06:00 [pubmed]
PHST- 2021/10/15 06:01 [medline]
PHST- 2021/09/27 00:00 [pmc-release]
AID - 10.3389/fmed.2021.713824 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Sep 27;8:713824. doi: 10.3389/fmed.2021.713824. 
      eCollection 2021.